Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in ...
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H AI-powered HER2 quantification continuous score (QCS) and tumor ...
New AI-driven tool converts common histology images into detailed, multi-layered cancer markers, promising faster, more accurate diagnostics and improved patient outcomes. Study: Accelerating ...
News Medical on MSN
MSK researchers solve a key colorectal cancer mystery
A new study from Memorial Sloan Kettering Cancer Center finds that in colorectal cancer, not all regulatory T cells are ...
In this interview, we spoke with Associate Professor Diana Mechtcheriakova about how lymphoid structures and germinal centers are unlocking new prognostic insights into colorectal cancer, and with ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback